Abstract Details

Title The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Topic Multiple Sclerosis

Presentation(s) P11 - Poster Session 11 (5:30 PM-6:30 PM)

Poster/Presentation
Number 6-002

Objective To evaluate the economic impact of MS, specifically the impact on employment and utilization of healthcare resources.

Background

NARCRMS is a longitudinal registry that collects information on MS from 26 sites across the United States and Canada. Clinical and imaging data and the impact of MS on daily life is examined longitudinally. The economic impact of MS at enrollment is reported here.

Design/Methods

The Health-Related Productivity and Health Resource Utilization (HEOR) questionnaires are completed at enrollment, annual and exacerbation visits by all subjects and form the basis of this communication.

Results 1047 subjects were enrolled and 1042 completed the HEOR case report forms (CRFs). In this mildly affected group, the median EDSS was 1.5 (IQR 1.0, 2.5) and 69% (723) were employed full/part time, with a third of subjects unemployed. During the week prior to reporting, 79 (11%) reported that MS kept them from work, 226 (31%) reported that MS impacted work, 280 (27%) reported that MS kept them from completing household chores and 295 (28%) reported that MS impacted household chores. In a multivariate analysis, fatigue was the leading symptom reported to impact work and household chores (p=0.001). Cognitive complaints and bladder disturbances were also reported but neither achieved statistical significance. Only 77 (7%) relapses were reported since enrollment. In the 3 months prior to enrollment, 34 (3%) patients had inpatient hospital stays, 55 (5%) visited the emergency room, 200 (19%) visited a general practitioner and 784 (75%) visited a neurologist.

Conclusions

This cohort represents MS with mild impairments, MS seems to impact patients from reaching their full potential at work/home from the earliest stages of this disease. Overwhelmingly, fatigue was identified as the cause. The impact of identifying an effective treatment for this symptom of MS cannot be overstated.

This abstract is presented on behalf of NARCRMS Investigators and Industry Advisory Board.

Authors/Disclosures
Yang Mao-Draayer, MD (University of Michigan, Department of Neurology) PRESENTER	Dr. Mao-Draayer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen Idec. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme-Sanofi. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizone. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen Idec. The institution of Dr. Mao-Draayer has received research support from NIH .
Kottil W. Rammohan, MD (University of Miami)	Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. The institution of Dr. Rammohan has received research support from Genentech. The institution of Dr. Rammohan has received research support from Genzyme. The institution of Dr. Rammohan has received research support from EMD Serono. The institution of Dr. Rammohan has received research support from Alexion.
David K. Li, MD (University of British Columbia)	Dr. Li has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Academy of Health Care Learning. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Consortium of MS Centers.
June Halper, RN, ANP (CMSC)	Ms. Halper has nothing to disclose.
Sara McCurdy Murphy	No disclosure on file
Audrey Brown	No disclosure on file
Jesse Wilkerson	No disclosure on file
Lisa Patton (SSS/DLH, NARCRMS Operations Center)	No disclosure on file
Briana Bratcher (DLH)	No disclosure on file

��ɫ��

��ɫ��